Metabolic diseases like diabetes are increasingly widespread, and research for this class of diseases relies on discovering and quantifying biomarkers to elucidate underlying mechanisms and uncover novel drug targets. Our portfolio of metabolic assays are well suited for metabolic disease research in vitro, in vivo, and in situ, and offer novel tools for your research workflow from start to finish.
Metabolic diseases are systemic and manifest with a variety of biological changes, from autophagy dysfunction to altered blood coagulation. For easy detection of a wide range of metabolic biomarkers, we offer fast and pre-validated metabolic assay reagents, kits, and imaging systems. For targeted binding studies, we also provide target-specific radiolabeled reagents.
Our products for metabolic disease research include:
- LANCE® TR-FRET technology
- AlphaLISA® immunoassay kits
- Alpha reagents for AlphaLISA
- DELFIA® TRF technology
- Cellular, tissue, and in vivo imaging systems
- Target-specific radiolabeled ligands, carbohydrates, lipids, and steroids
The range of tools offered allows for the detection and quantitation of many key biomolecules in metabolic disease research. Gain precise insight on disease biomarkers like c-reactive protein, fibrinogen, IGF, FGF, insulin and glucagon, leptin and ghrelin, adiponectin, and factor VIII.
